Literature DB >> 29200144

Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.

David Buchbinder1, Mikko Seppanen2, V Koneti Rao3, Gulbu Uzel3, Diane Nugent1.   

Abstract

Novel primary immunodeficiency disorders are being identified with next generation sequencing technologies. We describe 1 patient with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) haploinsufficiency who had recurrent enhancing brain lesions, nodular pulmonary infiltrates, hepatosplenomegaly, immune cytopenias, as well as progressive hypogammaglobulinemia and lymphopenia. We describe a second patient with activated p110δ syndrome (APDS)/p110δ activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI) in association with recurrent respiratory tract infections, Epstein-Barr virus infection, lymphadenopathy, elevated serum IgM, and progressive lymphopenia. These presentations highlight the need for astute clinical judgment in the evaluation of patients with potential primary immunodeficiency disorders.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29200144      PMCID: PMC5984070          DOI: 10.1097/MPH.0000000000001003

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  10 in total

Review 1.  Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Authors:  Rodrigo Dienstmann; Jordi Rodon; Violeta Serra; Josep Tabernero
Journal:  Mol Cancer Ther       Date:  2014-04-18       Impact factor: 6.261

2.  Clinical features that identify children with primary immunodeficiency diseases.

Authors:  Anbezhil Subbarayan; Gloria Colarusso; Stephen M Hughes; Andrew R Gennery; Mary Slatter; Andrew J Cant; Peter D Arkwright
Journal:  Pediatrics       Date:  2011-04-11       Impact factor: 7.124

Review 3.  New treatments for inflammatory rheumatic disease.

Authors:  Carlo Selmi; Elena Generali; Marco Massarotti; Gerolamo Bianchi; Carlo A Sciré
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

4.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

5.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Authors:  Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel
Journal:  Nat Immunol       Date:  2013-10-28       Impact factor: 25.606

Review 6.  Advances in basic and clinical immunology in 2014.

Authors:  Javier Chinen; Luigi D Notarangelo; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2015-05       Impact factor: 10.793

7.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440

Review 8.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

Review 9.  Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.

Authors:  D Gardner; L E Jeffery; D M Sansom
Journal:  Am J Transplant       Date:  2014-08-06       Impact factor: 8.086

10.  Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.

Authors:  Ivan Angulo; Oscar Vadas; Fabien Garçon; Edward Banham-Hall; Vincent Plagnol; Timothy R Leahy; Helen Baxendale; Tanya Coulter; James Curtis; Changxin Wu; Katherine Blake-Palmer; Olga Perisic; Deborah Smyth; Mailis Maes; Christine Fiddler; Jatinder Juss; Deirdre Cilliers; Gašper Markelj; Anita Chandra; George Farmer; Anna Kielkowska; Jonathan Clark; Sven Kracker; Marianne Debré; Capucine Picard; Isabelle Pellier; Nada Jabado; James A Morris; Gabriela Barcenas-Morales; Alain Fischer; Len Stephens; Phillip Hawkins; Jeffrey C Barrett; Mario Abinun; Menna Clatworthy; Anne Durandy; Rainer Doffinger; Edwin R Chilvers; Andrew J Cant; Dinakantha Kumararatne; Klaus Okkenhaug; Roger L Williams; Alison Condliffe; Sergey Nejentsev
Journal:  Science       Date:  2013-10-17       Impact factor: 47.728

  10 in total
  2 in total

Review 1.  Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.

Authors:  Emily M Mace
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 2.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.